NSI-189 is a synthetic small molecule — a benzylpiperazine-aminopyridine, not a peptide — developed by Neuralstem as a candidate treatment for major depressive disorder. Among nootropic research chemicals it is unusual: it actually reached human clinical trials, including a randomized Phase 2. That trial record is also why its story is more sobering than the marketing suggests. This article sorts the claimed benefits by source class — what human trials measured, what preclinical animal and cell work reported, and what is purely community-reported.
The headline belongs at the top, not buried under the neurogenesis story: NSI-189's Phase 2 trial failed its primary endpoint for depression, and clinical development was discontinued. The compound was well tolerated over the trial window and some secondary, subject-rated signals were reported, but the prospectively-defined efficacy measure was not met. Each benefit below is labeled by its evidence source so the strength of each claim is visible.
Research-context information only. NSI-189 is an investigational compound studied in human clinical trials but not approved by the FDA; its clinical program was discontinued, and material sold today is a research chemical labeled not for human consumption. Protocols, doses, and reactions reported below come from published clinical trials, preclinical research, and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
How NSI-189 Works (Proposed, Partially Characterized)
The original development rationale was stimulation of neurogenesis — the proliferation and differentiation of neural stem cells in the subgranular zone of the hippocampus. The precise molecular target was never fully defined in the published record, so the mechanism is best read as proposed rather than established.
Preclinical work associates NSI-189 with hippocampal neural stem cell proliferation, increased expression of trophic factors including BDNF, and enhanced long-term potentiation (LTP) in hippocampal slices, with those plasticity effects tied to TrkB and Akt pathway activation (Liu et al., 2019, PMID 30408487). In the human Phase 2, an associated hippocampal-volume increase on MRI was reported. The accurate framing is that NSI-189's "neurogenic" label rests on preclinical models plus a hippocampal-volume MRI marker — not on a confirmed molecular target, and not on a demonstration that it increases neurogenesis in humans. Dose discussion belongs to the trial and community sources below, not to any validated enhancement protocol.
What the Human Trials Actually Showed (Including the Failed Phase 2)
This is the load-bearing evidence, because human data on a research nootropic is rare. The Phase 1B study (Fava et al., 2016, PMID 26643541) — a randomized, double-blind, placebo-controlled multiple-dose-escalation study in patients with major depressive disorder — tested 40, 80, and 120 mg/day over 28 days and reported the compound was relatively well tolerated at all doses with no serious adverse effects. It described preliminary signals of symptom improvement, but it was a small early-phase safety study, not powered to prove efficacy.
The pivotal Phase 2 (Papakostas et al., 2020, PMID 30626911) is where the story turns. It randomized 220 outpatients with MDD to 40 mg/day, 80 mg/day, or placebo over 12 weeks, using a sequential-parallel comparison design to improve signal detection. The primary endpoint — change in MADRS versus placebo — was not met: the 40 mg arm reached p=0.224 and the 80 mg arm p=0.344, neither statistically significant. The 40 mg dose showed greater reductions on two subject-rated secondary scales (the Symptoms of Depression Questionnaire and the Cognitive and Physical Functioning Questionnaire, p=0.044 for the pooled SDQ analysis), and a hippocampal-volume increase was reported. Those are secondary and subject-rated; they do not rescue a failed primary endpoint, and after the 2017 top-line miss the depression program did not advance to a successful Phase 3.
A later post-hoc subgroup analysis of the same dataset (Johe et al., 2020, PMID 32722729) reported that the 80 mg dose benefited moderately-depressed patients (baseline MADRS < 30) but not severely-depressed ones. Post-hoc subgroup findings are hypothesis-generating, not confirmatory — they do not change the fact that the prospectively-defined primary endpoint failed.
Ready to buy? Compare the verified research-grade source on our best NSI-189 source page, or browse all coupon codes for up to 50% off.
